Legend Biotech ADSs Fall After Company Announces Public Offering

Dow Jones06-18
 

By Stephen Nakrosis

 

The American depositary shares of Legend Biotech were trading lower in the after-hours market, following news the company commenced an underwritten public offering of $225 million of ADSs.

After the bell, the cell therapy company's ADSs were trading 8% lower, at $30.84. The ADSs finished the day's regular session with a gain of less than 1%, closing at $33.52.

Year to date, the company's ADSs have gained over 54%.

 

Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

 

(END) Dow Jones Newswires

June 17, 2026 17:40 ET (21:40 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment